Cancer Biology: Infectious Tumour Cells

Similar documents
BIOLOGICAL SCIENCES. Catching Cancer SAMUEL RUTLEDGE

Transplantation. Immunology Unit College of Medicine King Saud University

PROBLEMS WITH THE IMMUNE SYSTEM. Blood Types, Transplants, Allergies, Autoimmune diseases, Immunodeficiency Diseases

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms. Table 2: Innate Immunity: First Lines of Defense

SEVENTH EDITION CHAPTER

Autoimmunity & Transplantation. Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Overview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Animal Models to Understand Immunity

Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions

Immunology Lecture 4. Clinical Relevance of the Immune System

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard

Transplantation and Cancer

Transplantation Immunology Booklet C

The Lymphatic System and Body Defenses

Chapter 35 Active Reading Guide The Immune System

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Setting The setting was secondary care. The economic analysis was carried out in Canada.

SKIN CANCER AFTER HSCT

NATURAL KILLER T CELLS EBOOK

HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People

Haplo vs Cord vs URD Debate

Immunodeficiencies HIV/AIDS

Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA

IN UTERO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CANINES: THE GESTATIONAL WINDOW OF OPPORTUNITY TO MAXIMIZE ENGRAFTMENT

- Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ.

Principles of Adaptive Immunity

HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH CHILDREN

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

Immune system. Aims. Immune system. Lymphatic organs. Inflammation. Natural immune system. Adaptive immune system

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

Higher Human Biology Unit 1: Human Cells

IMMUNE SYSTEM. Biology 2201

IMMUNE SYSTEM. Biology What is a disease? Other than an injury, any change in the body that interferes with the normal functioning of the body.

BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016

Basic Immunology Final Exam

Do Viruses Play a Role in Childhood Leukaemia?

Corporate Medical Policy

Clinical Policy: Donor Lymphocyte Infusion

Foundations in Microbiology

OU Human Physiology: Transplantation and Cancer Immunology *

- A cancer is an uncontrolled, independent proliferation of robust, healthy cells.

Human Leukocyte Antigens and donor selection

Immunodeficiency. (2 of 2)

Biological Therapies for Cancer: Questions and Answers

Stem Cell Transplantation for Severe Aplastic Anemia

Tumours in the donor: what is the risk?

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

Overview. Barriers help animals defend against many dangerous pathogens they encounter.

BESIDES their beneficial effect in retarding

XIV. HLA AND TRANSPLANTATION MEDICINE

Robert B. Colvin, M.D. Department of Pathology Massachusetts General Hospital Harvard Medical School

Topics in Parasitology BLY Vertebrate Immune System

A factor which brings about a mutation is called a mutagen. Any agent that causes cancer is called a carcinogen and is described as carcinogenic.

Immunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Tuesday 15 January 2013 Afternoon

MCAT Biology - Problem Drill 16: The Lymphatic and Immune Systems

The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep

An Overview of Blood and Marrow Transplantation

use of Calcineurin University of Ottawa Canada The 7 th International Congress on Autoimmunity. Ljubljana- Slovenia. May 5-9, 2010

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Immunity. Avian Physiology

Blood Types and Genetics

Chapter 40 Section 2 The Immune System

Introduction to Hematopoietic Stem Cell Transplantation

Immune System Notes Innate immunity Acquired immunity lymphocytes, humoral response Skin lysozyme, mucus membrane

Activation of cellular proto-oncogenes to oncogenes. How was active Ras identified?

Bihong Zhao, M.D, Ph.D Department of Pathology

DEPARTMENT OF CLINICAL HEMATOLOGY

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

BIT 120. Copy of Cancer/HIV Lecture

Histocompatibility antigens

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1

September 20, Submitted electronically to: Cc: To Whom It May Concern:

Corporate Medical Policy

An Introduction to Bone Marrow Transplant

KEY CONCEPT Germs cause many diseases in humans.

Clonal Origin and Evolution of a Transmissible Cancer

Corporate Medical Policy

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

Corporate Medical Policy

Early Detection of Cancer Using Circulating Tumour DNA: Feasibility and Field Trial Using the Unique Tasmanian Devil Transmissible Cancer

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Donatore HLA identico di anni o MUD giovane?

Cover Page. The handle holds various files of this Leiden University dissertation.

All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity

NAME TA. Problem sets will NOT be accepted late.

Blood Product Modifications: Leukofiltration, Irradiation and Washing

The diagnostic and prognostic value of genetic aberrations in resectable distal bile duct cancer Rijken, A.M.

The immune response and its role in renal transplant rejection

Patient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Transcription:

Cancer Biology: Infectious Tumour Cells Citation Published Version Accessed Citable Link Terms of Use Dingli, David, and Martin A. Nowak. 2006. Cancer biology: Infectious tumour cells. Nature 443(7107): 35-36. doi:10.1038/443035a May 18, 2011 10:14:05 AM EDT http://nrs.harvard.edu/urn-3:hul.instrepos:4318027 This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:hul.instrepos:dash.current.terms-ofuse#laa (Article begins on next page)

Infectious Cancer Cells David Dingli 1,2 and Martin A. Nowak 1 New evidence is mounting that cancer cells can evolve to become infectious agents and be transmitted between individuals. The current view of carcinogenesis is that normal cells are transformed into tumour cells by mutations that activate oncogenes, silence tumour suppressor genes or trigger genetic instabilities. As a consequence, every tumour is the result of a unique evolutionary process that begins in its individual host and ends with the elimination of the tumour or the death of the host. Two recent studies, however, suggest that tumour cells can behave like infectious agents and move from one host to another 1,2. It has long been suspected that canine transmissible venereal tumour (CTVT) is transferred between dogs by implantation of tumour cells from donor to the recipient, where the tumour grows as an allograft 3. Several lines of evidence provided indirect support for this hypothesis. The tumour can only be induced by the implantation of whole tumour cells but not by cell extracts or dead cells. Normal canine cells have 78 chromosomes but karyotypes of tumour cells isolated from different animals have shown a characteristic and persistent pattern of aneuploidy with 58 to 59 chromosomes 4. In addition, a LINE-1 insertion close to c-myc has been found in all tumour samples 5. If the allograft transfer hypothesis is correct, tumour cells from different animals should be genetically clustered and different from normal cells of the host animal. Formal proof of

the allograft hypothesis for CTVT was recently provided by Claudio Murgia, Robin Weiss and colleagues 1. They studied tumour and normal cells isolated from dogs harboring CTVT from three continents. Using a combination of dog leukocyte antigen (DLA) haplotyping, microsatellite DNA and mitochondrial DNA sequencing, they proved that all the tumours are closely related genetically and different from normal cells of the host dog 1. Sequencing of microsatellite DNA regions showed that tumours from different animals had less variability than what is observed within the most inbred breed of dogs. Therefore, the tumours could not arise from the separate transformations of cells within individual animals but were transmitted from one dog to another confirming the spread of this tumour from an ancestral clone. Moreover, by comparing tumour and various canine microsatellite markers, it was estimated that the clone had arisen between 250 and 2500 years ago making it the oldest known continuously replicating somatic cell line 1. In an independent study, Pearse and Swift 2 have reported that devil facial tumour disease is caused by horizontal tumour cell transmission between Tasmanian devils. Cancer cells isolated from different animals that harbored tumours of different age and size share the same aneuploid karyotype. Furthermore, one animal had a constitutional pericentric inversion of chromosome 5 but this abnormality was not found in any of the cells isolated from the tumour, providing further support that the tumour did not arise from host cells. Given that tumour cells can behave like infectious agents in some mammals, the question arises if infectious transmission of cancer can also occur in humans. There is no evidence (yet) for direct horizontal transmission of tumour cells between humans with

normal social contact. The only known physiological route for tumour cell transmission in humans is during pregnancy. Every year about 3,500 pregnant women in the United States have a concomitant malignancy. Transplacental transmission of lymphoma, acute leukaemia, melanoma and carcinoma from mother to fetus have been observed 6. Acute leukaemia cells have also been transferred between fetuses (in mothers with a multiple pregnancy) followed by the development of disease in both fetuses 6. Organ transplantation represents another possible route of tumour cell transmission between humans. The immunosuppressive therapy required for survival of the transplanted organ blunts immune surveillance and may facilitate engraftment and growth of donor derived tumour cells. Fortunately, the development of donor derived tumours in solid organ transplant recipients is rare (0.04%) 7. The main culprit seems to be malignant melanoma that is undetected in the donor at the time of organ harvest: in one report, metastatic melanoma developed in both kidney and liver recipients from a donor with occult disease 8. Another example is the transfer of haematological malignancy by haematopoietic stem cell transplantation 9. Again the frequency is low (0.06%). Finally, we came across one case report where a surgeon developed malignant fibrous histiocytoma after accidentally injuring his palm during surgical removal of the tumour from a patient 10. The transfer of tumour cells between individuals seems to be a rare event in humans. Differences in the human lymphocyte antigens may protect against successful tumour cell engraftment by inducing an immune response that eliminates the implanted cells. CTVT cells avoid immune mediated destruction by down-regulating DLA expression 1. This is an important adaptation since complete absence of DLA antigens

would allow natural killer cells to destroy the tumour, while normal expression of DLA antigens activates cytotoxic T-cells with a similar outcome. In many dogs, an immune attack against CTVT ultimately develops and leads to tumour eradication and immunity to re-challenge 3. This evidence also strengthens the hope that the immune system can be coached to eradicate established tumours in humans. The emergence of multi-cellular life forms required cooperation between cells of a given organism. Cancer entails loss of this cooperation, and from the perspective of evolutionary game theory cancer is a defector 11. Breakdown of cooperation can lead to the death of the host, but then the tumour also meets its own demise. Therefore, a tumour, which can be transmitted from one host to the next, maneuvers around the specific evolutionary mechanism that is meant to control it. Why is cancer in general not transmissible between people? A main reason is tissue graft rejection caused by MHC incompatibility. The cancer cells of the donor should induce a vigorous immune response in a healthy recipient. Tumour transfer in mice is only possible between syngeneic animals (that share the same MHC) or if the recipient is severely immunosuppressed. This leads to the interesting speculation, suggested by Murgia et al 1, that a main reason for MHC diversity in humans and other vertebrates is to ensure that cancer is not an infectious disease. Author affiliations 1 Program for Evolutionary Dynamics, Department of Organismic and Evolutionary Biology, Department of Mathematics, Harvard University, Cambridge, MA 02138, USA 2 Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. Email: dingli.david@mayo.edu; martin_nowak@harvard.edu

References 1. Murgia, C., Pritchard, J.K., Kim, S.Y., Fassati, A., Weiss, R.A. Clonal origin and age of a naturally transmissible cancer. Cell In press (2006). 2. Pearse, A. M. & Swift, K. Allograft theory: transmission of devil facial-tumour disease. Nature 439, 549 (2006). 3. Das, U. & Das, A. K. Review of canine transmissible venereal sarcoma. Vet Res Commun 24, 545-56 (2000). 4. Wright, D. H., Peel, S., Cooper, E. H. & Hughes, D. T. Transmissible venereal sarcoma of dogs. A histochemical and chromosomal analysis of tumours in Uganda. Rev Eur Etud Clin Biol 15, 155-60 (1970). 5. Katzir, N., Arman, E., Cohen, D., Givol, D. & Rechavi, G. Common origin of transmissible venereal tumors (TVT) in dogs. Oncogene 1, 445-8 (1987). 6. Tolar, J. & Neglia, J. P. Transplacental and other routes of cancer transmission between individuals. J Pediatr Hematol Oncol 25, 430-4 (2003). 7. Kauffman, H. M., McBride, M.A., Cherikh, W.S., Spain, P.C., Marks, W.H., Roza, A.M. Transplant tumor registry: donor related malignancies. Transplantation 74, 358-362 (2002). 8. Morris-Stiff, G. et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant 4, 444-6 (2004). 9. Sala-Torra, O. et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12, 511-7 (2006). 10. Gartner, H. V. et al. Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. N Engl J Med 335, 1494-6 (1996). 11. Nowak, M. A. Evolutionary dynamics. Evolutionary Dynamics: exploring the equations of life (Belknap/Harvard University Press) (2006).